THE 60-SECOND GUIDE
Desmopressin
Approved human use · product-specific labels.
Guide prepared November 13, 2026 · profile review dates retained
What is it?
Desmopressin is a modified version of vasopressin, the hormone that helps the kidneys conserve water. Particular medicinal formulations also raise clotting-factor activity and have uses in selected bleeding disorders. The formulation and diagnosis determine which role applies. [1]
Potential benefits
Has defined uses in selected water-balance and bleeding disorders. Can promote kidney water retention or release of clotting factors, depending on route and indication. [1]
Evidence & its limits
Retaining too much water can dangerously lower blood sodium. The injection label carries a boxed warning for severe hyponatremia, including seizures, coma, and death; fluid restrictions, contraindications, and sodium monitoring are central to its safe use. [1]
Risks & unknowns
Hyponatremia and water intoxication can be serious. Fluid instructions and monitoring are indication-specific. [1]
Status & scope
Approved human use · product-specific labels. Read the full record for product, formulation and indication-specific status; a biological role or measured response is not a treatment approval. [1]
The question to ask
Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.
CHECK THE RECORD
Sources & review
- Full evidence record, references and review dates
- FDA Drugs@FDA database
- MedlinePlus: medication-specific uses and precautions
- Desmopressin injection prescribing information
Guide prepared November 13, 2026 · profile review dates retained. Condensed from the linked site evidence record. This format update is not a new clinical review of every source. Consult the full profile for its evidence-review dates and targeted updates.
Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.